CompanyIMRNNasdaqCarlton, Victoria, C3

Immuron Ltd

Immuron develops orally delivered targeted polyclonal antibodies for infectious diseases.

SEC EDGAR ClinicalTrials.gov immuron.com.au

20-FSep 24Latest SEC filing, period to Jun 30

Sep 21Latest story

September 2026

Immuron presents pipeline and financial update at Coffee Microcaps conference

Sep 21PeopleImmuron Ltd

August 2026

Immuron outlines pipeline partnering push at Emerging Growth Conference

Aug 18PeopleImmuron Ltd

July 2026

Immuron hires Pullan Consulting to shop IMM-529, cites CDI deal comparables

Jul 27PeopleImmuron Ltd

Immuron hires Pullan Consulting to find IMM-529 partner for C. diff drug

Jul 6Regulatory decisionImmuron Ltd